Based on the Lantern Pharma Inc stock forecast from 0 analysts, the average analyst target price for Lantern Pharma Inc is not available over the next 12 months. Lantern Pharma Inc’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of Lantern Pharma Inc is Bearish, which is based on 2 positive signals and 6 negative signals. At the last closing, Lantern Pharma Inc’s stock price was USD 3.74. Lantern Pharma Inc’s stock price has changed by -10.74% over the past week, +8.56% over the past month and -8.11% over the last year.
No recent analyst target price found for Lantern Pharma Inc
No recent average analyst rating found for Lantern Pharma Inc
Company Overview Lantern Pharma Inc
Lantern Pharma Inc., a clinical stage biotechnology company, focuses on artificial intelligence, machine learning, and genomic data to streamline the drug development process. Its product pipeline comprises LP-300, which is in phase 2 clinical trial in combination therapy for never-smokers with non-small cell lung cancer adenocarcinoma; LP-184, which is in phase 1 clinical trial for the treatment of solid tumor, such as pancreatic, breast, bladder, and lung cancers, and glioblastoma and other central nervous system cancers; and LP-284, which is in phase 1 clinical trial for the treatment of non-Hodgkin's lymphomas, including mantle cell lymphoma and double hit lymphoma. The company develops STAR-001, which is in preclinical development for the treatment of glioblastoma, brain metastases, atypical teratoid rhabdoid tumors, and pediatric rare disease designation. In addition, it provides ADC program, an antibody drug conjugate therapeutic approach for cancer treatment. Further, the company's artificial intelligence platform RADR uses big data analytics and machine learning for combining molecular data. Lantern Pharma Inc. has a strategic AI-driven collaboration with Oregon Therapeutics to optimize the development of its first-in-class protein disulfide isomerase inhibitor drug candidate XCE853 in novel and targeted cancer indications. The company was incorporated in 2013 and is headquartered in Dallas, Texas. Read Less
Lantern Pharma Inc., a clinical stage biotechnology company, focuses on artificial intelligence, machine learning, and genomic data to streamline the drug development process. Its product pipeline comprises LP-300, which is in phase 2 clinical trial in combination therapy for nev...Read More
Frequently Asked Questions About Lantern Pharma Inc (LTRN) Stock
Stock Target Advisor's fundamental analysis for Lantern Pharma Inc's stock is Bearish.
Unfortunately we do not have enough data on LTRN's stock to indicate if its a good dividend stock.
Unfortunately we do not have enough data on LTRN's stock to indicate what its average analyst target is.
Unfortunately we do not have enough data on LTRN's stock to indicate if its overvalued.
The last closing price of LTRN's stock was USD 3.74.
The most recent market capitalization for LTRN is USD 0.04B.
Unfortunately we do not have enough analyst data on LTRN's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains Lantern Pharma Inc's stock.
As per our most recent records Lantern Pharma Inc has 21 Employees.
Lantern Pharma Inc's registered address is 1920 McKinney Avenue, Dallas, TX, United States, 75201.
You can get more information about it from Lantern Pharma Inc's website at https://www.lanternpharma.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Low volatility
The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.
Positive free cash flow
The company had positive total free cash flow in the most recent four quarters.
What not to like
Below median dividend returns
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
Poor risk adjusted returns
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
Low market capitalization
This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Low Earnings Growth
This stock has shown below median earnings growth in the previous 5 years compared to its sector
Overpriced on free cash flow basis
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Frequently Asked Questions About Lantern Pharma Inc (LTRN) Stock
Stock Target Advisor's fundamental analysis for Lantern Pharma Inc's stock is Bearish.
Unfortunately we do not have enough data on LTRN's stock to indicate if its a good dividend stock.
Unfortunately we do not have enough data on LTRN's stock to indicate what its average analyst target is.
Unfortunately we do not have enough data on LTRN's stock to indicate if its overvalued.
The last closing price of LTRN's stock was USD 3.74.
The most recent market capitalization for LTRN is USD 0.04B.
Unfortunately we do not have enough analyst data on LTRN's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains Lantern Pharma Inc's stock.
As per our most recent records Lantern Pharma Inc has 21 Employees.
Lantern Pharma Inc's registered address is 1920 McKinney Avenue, Dallas, TX, United States, 75201.
You can get more information about it from Lantern Pharma Inc's website at https://www.lanternpharma.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for LTRN !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
